US 12,257,248 B2
Bronchodilators for treating obstructive lung disease
Stephen Liggett, Tampa, FL (US); James Leahy, Tampa, FL (US); Donghwa Kim, Tampa, FL (US); and Steven An, Highland Park, NJ (US)
Assigned to University of South Florida, Tampa, FL (US); and Rutgers, The State University of New Jersey, New Brunswick, NJ (US)
Filed by University of South Florida, Tampa, FL (US); and Rutgers, The State University of New Jersey, New Brunswick, NJ (US)
Filed on Sep. 1, 2021, as Appl. No. 17/464,233.
Claims priority of provisional application 62/706,654, filed on Sep. 1, 2020.
Prior Publication US 2022/0062274 A1, Mar. 3, 2022
Int. Cl. A61K 31/4745 (2006.01); A61K 31/122 (2006.01); A61K 31/444 (2006.01)
CPC A61K 31/4745 (2013.01) [A61K 31/122 (2013.01); A61K 31/444 (2013.01)] 16 Claims
 
1. A method for treating an obstructive lung disease in a patient in need thereof, comprising administering to the patient a compound having the formula:

OG Complex Work Unit Chemistry
or a pharmaceutically acceptable salt thereof, wherein
Z1 is O, S, or NRa; wherein Ra is H, C1-8alkyl, or C1-8alkoxy;
Z2 is O, S, or NRb; wherein Rb is H, C1-8alkyl, or C1-8alkoxy;
R1 is selected from Ra, ORa, N(Ra)2, F, Cl, Br, I, NO2, CN, wherein Ra is in each case selected from H, C1-8alkyl, C2-8alkenyl; C2-8alkynyl;
R2 is selected from Rb, ORb, N(Rb)2, F, Cl, Br, I, NO2, CN, wherein Rb is in each case selected from H, C1-8alkyl, C2-8alkenyl; C2-8alkynyl;
R3 is selected from Rc, ORc, N(Rc)2, F, Cl, Br, I, NO2, CN, wherein Rc is in each case selected from H, C1-8alkyl, C2-8alkenyl; C2-8alkynyl;
wherein any two or more of R1, R2, and R3 may together form a ring; and
X2 is N;
R6 is selected from Rd, ORd, N(Rd)2, F, Cl, Br, I, NO2, CN, wherein Rd is in each case selected from H, C1-8alkyl, C2-8alkenyl; C2-8alkynyl;
R7 is selected from Re, ORe, N(Re)2, F, Cl, Br, I, NO2, CN, wherein Re is in each case selected from H, C1-8alkyl, C2-8alkenyl; C2-8alkynyl;
R8 is selected from Rf, ORf, N(Rf)2, F, Cl, Br, I, NO2, CN, wherein Rf is in each case selected from H, C1-8alkyl, C2-8alkenyl; C2-8alkynyl;
wherein any two or more of R6, R7, and R8 may together form a ring; and
wherein R8 may form a ring with Rb,
wherein the obstructive lung disease is asthma, chronic obstructive pulmonary disease, emphysema, bronchitis, cystic fibrosis, bronchiectasis, bronchiolitis, or allergic bronchopulmonary aspergillosis.